EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Effects of the phosphodiesterase 2 inhibitor BI 474121 on central nervous system cyclic guanosine monophosphate concentrations: Translational studies

Sebastiaan van Kraaij iD, Rainer-Georg Goeldner, Holger Rosenbrock, Geert Jan Groeneveld iD, Philip Kremer, Jennifer Schaible, Janos Zambori, Christian Schultheis iD

British Journal of Clinical Pharmacology · 2024

DOI: 10.1111/bcp.16137 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Sebastiaan van Kraaij und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Human Drug Research, Leiden, Netherlands. Hauptthemen laut MEDLINE: Cyclic GMP, Cyclic Nucleotide Phosphodiesterases, Type 2, Dose-Response Relationship, Drug. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Phosphodiesterase 2 (PDE2) regulates intracellular cyclic adenosine monophosphate and guanosine monophosphate (cAMP/cGMP) levels, which contribute to processes crucial for learning and memory. BI 474121, a potent and selective PDE2 inhibitor, is in development for treating cognitive impairment associated with schizophrenia.

Methods

The effects of BI 474121 on cGMP concentrations were first assessed in rat cerebrospinal fluid (CSF) to demonstrate central nervous system (CNS) and functional target engagement. Next, a Phase I study in healthy participants assessed the pharmacokinetics of BI 474121 in CSF vs . plasma, the pharmacodynamics of BI 474121 by measuring cGMP concentrations in the CSF, and the safety of BI 474121.

Results

In rats, BI 474121 was associated with a dose‐dependent increase (71% at the highest dose tested [3.0 mg kg −1 ]) in cGMP levels in the CSF relative to vehicle ( P < 0.001). In healthy participants, the maximum‐measured concentration CSF‐to‐plasma ratio for BI 474121 exposure was similar following single oral doses of BI 474121 2.5, 10, 20 and 40 mg (dose‐adjusted geometric mean: 8.96% overall). BI 474121 2.5–40 mg administration in healthy participants also increased cGMP levels in CSF (maximum exposure‐related change from baseline ratio, BI 474121: 1.44–2.20 vs . placebo: 1.26). The most common treatment‐emergent adverse event (AE) was mild‐to‐moderate post‐lumbar puncture syndrome, which resolved with standard treatment. No AEs of special interest were observed.

Conclusions

BI 474121 crosses the blood–brain barrier to inhibit PDE2, supporting cGMP as a translational marker to monitor CNS target engagement. These findings promote further clinical development of BI 474121. ClinicalTrials.gov number (NCT04672954).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclic GMPCyclic Nucleotide Phosphodiesterases, Type 2Dose-Response Relationship, DrugAdultAnimalsFemaleHumansMaleMiddle AgedRatsYoung AdultCentral Nervous SystemDouble-Blind MethodHealthy VolunteersPhosphodiesterase InhibitorsTranslational Research, BiomedicalRats, Wistar

Stichwörter der Autor:innen

drug developmentpharmacodynamicspharmacokineticsschizophreniatranslational research

Substanzen

Cyclic GMPCyclic Nucleotide Phosphodiesterases, Type 2Phosphodiesterase Inhibitors

Autor:innen und Institutionen

  • Centre for Human Drug Research, Leiden, Netherlands.
  • Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.

ORCID-Profile: Sebastiaan van Kraaij, Geert Jan Groeneveld, Christian Schultheis

Förderung

  • Boehringer Ingelheim

Zitieren

APA

van Kraaij, S., Goeldner, R. G., Rosenbrock, H., Groeneveld, G. J., Kremer, P., Schaible, J., Zambori, J., & Schultheis, C. (2024). Effects of the phosphodiesterase 2 inhibitor BI 474121 on central nervous system cyclic guanosine monophosphate concentrations: Translational studies. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16137

Vancouver

van Kraaij S, Goeldner RG, Rosenbrock H, Groeneveld GJ, Kremer P, Schaible J, et al. Effects of the phosphodiesterase 2 inhibitor BI 474121 on central nervous system cyclic guanosine monophosphate concentrations: Translational studies. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16137

BibTeX
@article{vanKraaij2024,
  author = {van Kraaij, Sebastiaan and Goeldner, Rainer-Georg and Rosenbrock, Holger and Groeneveld, Geert Jan and Kremer, Philip and Schaible, Jennifer and Zambori, Janos and Schultheis, Christian},
  title = {Effects of the phosphodiesterase 2 inhibitor BI 474121 on central nervous system cyclic guanosine monophosphate concentrations: Translational studies},
  journal = {British Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1111/bcp.16137}
}
Kostenlos starten →